Long-term predictive models and algorithmic financial forecasts projecting out to the year 2030 estimate that Corcept Therapeutics shares could trade within an expanded target range of $130 to over $240 per share. These speculative long-term valuations are heavily dependent on successful commercial execution, widespread label expansions for its pipeline drugs, continued revenue growth, and sustained profitability in the biopharmaceutical sector.